Heinz Weidenthaler, Dr med

VP Clinical Strategy AbNCoV2 & MVA-BN
Bavarian Nordic
Martinsried, Bayern, Germany

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB747 - Immune Responses of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in an RSV Human Challenge Trial (HCT) in Healthy Adult Participants

  Thursday, October 20, 2022
  2:09 PM – 2:21 PM US ET